TuHURA Biosciences (HURA) Expected to Announce Quarterly Earnings on Wednesday

TuHURA Biosciences (NASDAQ:HURA) is expected to post its results before the market opens on Wednesday, February 25th. Analysts expect TuHURA Biosciences to post earnings of ($0.1233) per share for the quarter.

TuHURA Biosciences Stock Performance

Shares of TuHURA Biosciences stock opened at $1.15 on Monday. The stock has a market capitalization of $69.83 million, a P/E ratio of -2.30 and a beta of 0.12. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $4.44. The stock’s 50-day simple moving average is $0.81 and its 200 day simple moving average is $1.83.

Institutional Investors Weigh In On TuHURA Biosciences

Several large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after acquiring an additional 307,260 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of TuHURA Biosciences by 209.8% during the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock worth $61,000 after purchasing an additional 54,051 shares in the last quarter. New York State Common Retirement Fund bought a new position in shares of TuHURA Biosciences in the second quarter worth approximately $97,000. Goldman Sachs Group Inc. bought a new stake in TuHURA Biosciences during the fourth quarter valued at approximately $30,000. Finally, Marshall Wace LLP purchased a new position in TuHURA Biosciences in the 2nd quarter worth approximately $79,000. Institutional investors own 0.62% of the company’s stock.

Wall Street Analysts Forecast Growth

HURA has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, January 22nd. Maxim Group reduced their price target on TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, TuHURA Biosciences has a consensus rating of “Moderate Buy” and an average target price of $9.00.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.